RECRUITING

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Talk to us

Conditions

Esophageal CancerGastric CancerHepatocellular CancerCervical Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.

Official Title

A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors

Quick Facts

Study Start:2023-01-12
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05438420

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
  2. * Subjects with histologically or cytologically confirmed advanced or metastatic esophageal, gastric/GEJ, hepatocellular and cervical cancers who have progressed on treatment with an anti-PD1 or anti PD-L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other therapies
  3. * Have measurable disease per RECIST v 1.1. as assessed by local site investigator/radiology
  4. * Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  5. * Life expectancy of at least 3 months
  1. * A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment or breast-feeding women
  2. * Concomitant use of strong inhibitors and inducers of CYP1A2, 2J2, 2C19, 2D6, and 3A4/5 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
  3. * Concomitant use of sensitive substrates of CYP2C9, 2C19, and 3A4 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
  4. * Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
  5. * Has had an allogeneic tissue/solid organ transplant

Contacts and Locations

Study Contact

Qurient Clinical Trial Information
CONTACT
+82-31-8060-1610
clinicaltrial_info@qurient.com

Study Locations (Sites)

University of Southern California
Los Angeles, California, 90033
United States
Norton Cancer Institute
Louisville, Kentucky, 40202
United States

Collaborators and Investigators

Sponsor: Qurient Co., Ltd.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-12
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2023-01-12
Study Completion Date2026-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Esophageal Cancer
  • Gastric Cancer
  • Hepatocellular Cancer
  • Cervical Cancer